SRX-1177 regulatory update

FDA granted Orphan Drug designation to SRX-1177 to treat stage IIB-IV malignant melanoma. SRX-1177 is in preclinical testing. The radiolabeled peptide binds to melanocortin 1 receptors ( MC1R) to iden...